- Conditions
- Interstitial Cystitis
- Interventions
- Onabotulinumtoxin A, injections upper aspect of trigone of urinary bladder, injections on posterior bladder wall excluding the trigone
- Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–28
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Facial Fine Lines
- Interventions
- Botox, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Miami, Florida • New York, New York • Nashville, Tennessee + 2 more
- Conditions
- Wrinkles, Photoaging, Fine Lines
- Interventions
- Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
- Procedure · Combination Product
- Lead sponsor
- Revision Skincare
- Industry
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
- Drug
- Lead sponsor
- Daniel Kaplan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania